Discovery of Chlorofluoroacetamide-Based Covalent Inhibitors for Severe Acute Respiratory Syndrome Coronavirus 2 3CL Protease

Authors :: Yuya Hirose
Naoya Shindo
Makiko Mori
Satsuki Onitsuka
Hikaru Isogai
Rui Hamada
Tadanari Hiramoto
Jinta Ochi
Daisuke Takahashi
Tadashi Ueda
Jose M. M. Caaveiro
Yuya Yoshida
Shigehiro Ohdo
Naoya Matsunaga
Shinsuke Toba
Michihito Sasaki
Yasuko Orba
Hirofumi Sawa
Akihiko Sato
Eiji Kawanishi
Akio Ojida
Source :: Journal of Medicinal Chemistry. 65:13852-13865
Publication Year :: 2022
Publisher :: American Chemical Society (ACS), 2022.
Abstract: The coronavirus disease 2019 (COVID-19) pandemic has necessitated the development of antiviral agents against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 3C-like protease (3CL

Subjects :: Cysteine Endopeptidases
SARS-CoV-2
Drug Discovery
Humans
Molecular Medicine
Protease Inhibitors
Cysteine
Peptides
Antiviral Agents
Coronavirus 3C Proteases
Peptide Hydrolases
COVID-19 Drug Treatment

Full Text Access

Tools